Ralph Venhaus

2.1k total citations
44 papers, 888 citations indexed

About

Ralph Venhaus is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ralph Venhaus has authored 44 papers receiving a total of 888 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Immunology and 14 papers in Molecular Biology. Recurrent topics in Ralph Venhaus's work include Immunotherapy and Immune Responses (21 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Cancer Research and Treatments (12 papers). Ralph Venhaus is often cited by papers focused on Immunotherapy and Immune Responses (21 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Cancer Research and Treatments (12 papers). Ralph Venhaus collaborates with scholars based in United States, Australia and United Kingdom. Ralph Venhaus's co-authors include Linda Pan, Lloyd J. Old, Achim A. Jungbluth, Anna C. Pavlick, Eric W. Hoffman, Toni Ricciardi, Mary Macri, Aileen Ryan, Patrick A. Ott and Jedd D. Wolchok and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Ralph Venhaus

43 papers receiving 877 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ralph Venhaus United States 14 555 443 302 123 103 44 888
Jan Martínek United States 7 492 0.9× 397 0.9× 244 0.8× 91 0.7× 57 0.6× 14 924
Nahoko Suzuki Japan 8 505 0.9× 393 0.9× 382 1.3× 49 0.4× 100 1.0× 11 1.1k
Xuexiang Du United States 10 504 0.9× 586 1.3× 204 0.7× 48 0.4× 25 0.2× 21 856
Iva Truxová Czechia 16 729 1.3× 648 1.5× 299 1.0× 42 0.3× 43 0.4× 24 1.2k
Sarah Maenhout Belgium 13 552 1.0× 425 1.0× 395 1.3× 33 0.3× 44 0.4× 13 889
Hideo Komita Japan 17 446 0.8× 408 0.9× 199 0.7× 39 0.3× 49 0.5× 27 650
Kalijn F. Bol Netherlands 21 1.3k 2.3× 1.1k 2.4× 523 1.7× 56 0.5× 163 1.6× 42 1.7k
Jan L. Fisher United States 20 825 1.5× 703 1.6× 412 1.4× 27 0.2× 129 1.3× 37 1.3k
Katy J. McCann United Kingdom 10 311 0.6× 180 0.4× 246 0.8× 96 0.8× 44 0.4× 16 563
Fengshu Zhao China 19 365 0.7× 456 1.0× 412 1.4× 83 0.7× 31 0.3× 49 872

Countries citing papers authored by Ralph Venhaus

Since Specialization
Citations

This map shows the geographic impact of Ralph Venhaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Venhaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Venhaus more than expected).

Fields of papers citing papers by Ralph Venhaus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Venhaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Venhaus. The network helps show where Ralph Venhaus may publish in the future.

Co-authorship network of co-authors of Ralph Venhaus

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Venhaus. A scholar is included among the top collaborators of Ralph Venhaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Venhaus. Ralph Venhaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Middleton, Mark R., Ioannis Karydis, Xin Lü, et al.. (2023). Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.. Journal of Clinical Oncology. 41(4_suppl). 398–398. 2 indexed citations
2.
Zamarin, Dmitriy, Kunle Odunsi, Emese Zsíros, et al.. (2022). Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.. Journal of Clinical Oncology. 40(16_suppl). 2600–2600. 5 indexed citations
3.
Hall, Peter E., Neal Ready, Amanda Johnston, et al.. (2020). Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer. Clinical Lung Cancer. 21(6). 527–533. 24 indexed citations
4.
5.
6.
Cohen, Adam D., Nikoletta Lendvai, Sarah Nataraj, et al.. (2019). Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunology Research. 7(4). 658–669. 14 indexed citations
7.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2019). Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).. Journal of Clinical Oncology. 37(15_suppl). 2032–2032. 43 indexed citations
8.
Callahan, Margaret K., Kunle Odunsi, Mario Sznol, et al.. (2017). Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 3069–3069. 23 indexed citations
9.
Reardon, David A., Thomas Kaley, Jörg Dietrich, et al.. (2017). Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.. Journal of Clinical Oncology. 35(15_suppl). 2042–2042. 41 indexed citations
10.
Slingluff, Craig L., Paul Schwarzenberger, Toni Ricciardi, et al.. (2017). Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.. Journal of Clinical Oncology. 35(15_suppl). TPS3106–TPS3106. 4 indexed citations
11.
Reardon, David A., Jörg Dietrich, Thomas Kaley, et al.. (2015). Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).. Journal of Clinical Oncology. 33(15_suppl). TPS2077–TPS2077. 3 indexed citations
12.
Chen, Ji‐Li, Andrea Tarlton, Sacha Gnjatic, et al.. (2014). NY‐ESO ‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO ‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO ‐1 fowlpox virus. International Journal of Cancer. 136(6). E590–601. 40 indexed citations
13.
14.
Sabado, Rachel Lubong, Anna C. Pavlick, Sacha Gnjatic, et al.. (2014). Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.. Journal of Clinical Oncology. 32(15_suppl). TPS9119–TPS9119. 3 indexed citations
15.
16.
Ott, Patrick A., Richard D. Carvajal, Neeta Pandit‐Taskar, et al.. (2012). Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational New Drugs. 31(2). 425–434. 121 indexed citations
17.
Sabado, Rachel Lubong, Anna C. Pavlick, Sacha Gnjatic, et al.. (2012). Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.. Journal of Clinical Oncology. 30(15_suppl). 2589–2589. 5 indexed citations
18.
Nicholaou, Theo, Weisan Chen, Ian D. Davis, et al.. (2011). Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunology Immunotherapy. 60(11). 1625–1637. 35 indexed citations
19.
Ott, Patrick A., Richard D. Carvajal, Neeta Pandit‐Taskar, et al.. (2009). Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). Journal of Clinical Oncology. 27(15_suppl). 9030–9030. 5 indexed citations
20.
Nicholaou, Theo, Lisa M. Ebert, Ian D. Davis, et al.. (2009). Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. Clinical Cancer Research. 15(6). 2166–2173. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Martínek Breakdown of academic impact, for papers by Nahoko Suzuki Breakdown of academic impact, for papers by Xuexiang Du Breakdown of academic impact, for papers by Iva Truxová Breakdown of academic impact, for papers by Sarah Maenhout Breakdown of academic impact, for papers by Hideo Komita Breakdown of academic impact, for papers by Kalijn F. Bol Breakdown of academic impact, for papers by Jan L. Fisher Breakdown of academic impact, for papers by Katy J. McCann Breakdown of academic impact, for papers by Fengshu Zhao
Rankless by CCL
2026